35 citations
,
August 2001 in “Journal of Cutaneous Medicine and Surgery” Tacrolimus is effective for various skin conditions with fewer side effects than cyclosporine.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
September 2019 in “Journal of Investigative Dermatology” Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.
July 2025 in “Journal of Investigative Dermatology” High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.
March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry” Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
August 2025 in “Saudi Pharmaceutical Journal” The ointment effectively treats neurodermatitis and chronic eczema without causing skin irritation.
September 2025 in “Experimental & Molecular Medicine” Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
April 2016 in “Journal of Investigative Dermatology” Blocking certain proteins can significantly regrow hair in severe alopecia areata.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
16 citations
,
March 2017 in “Oncotarget” SOCS3 treatment can prevent hair loss by stopping harmful immune responses.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
53 citations
,
July 2009 in “Cancer Research” Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
156 citations
,
August 2014 in “Cochrane library” Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
August 2002 in “British journal of ophthalmology” Surgical excision is the best treatment for SCC, but intralesional cidofovir might be a viable alternative.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
January 2024 in “Journal der Deutschen Dermatologischen Gesellschaft” Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.
2 citations
,
May 2023 in “The Journal of Immunology” NXC736 significantly reduced hair loss in mice with alopecia areata.
5 citations
,
November 2005 in “Journal of Investigative Dermatology” 1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
10 citations
,
May 2020 in “Dermatologic therapy” Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
April 2018 in “Journal of Investigative Dermatology”
August 2016 in “Journal of Investigative Dermatology” Scalp psoriasis features reversible hair loss and specific immune activation, with no significant hair follicle damage.
April 2021 in “Research Square (Research Square)” The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
9 citations
,
January 2017 in “Dermatology Online Journal” Some hair loss drugs can cause a unique type of hair loss that resembles both psoriasis and alopecia.